Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15731795 | 0.87 | PIK3R1 (0.39) | MAPTTP53NPC1RAB9AMAPK1 | |
| SCHEMBL8357983 | 0.87 | ALDH1A1 (0.41) | MAPTNPC1RAB9APKMALDH1A1 | |
| SCHEMBL6330031 | 0.86 | KMT2A (0.49) | AKR1C3MAPTNPC1RAB9AMAPK1 | |
| SCHEMBL29483984 | 0.86 | RAD51 (0.51) | AKR1C3MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1919863 | 0.86 | AKR1C3 (0.44) | AKR1C3MAPTTP53NPC1RAB9A | |
| SCHEMBL20050092 | 0.86 | ALDH1A1 (0.42) | MAPTTP53NPC1RAB9AUSP2 | |
| SCHEMBL8360878 | 0.85 | DRD2 (0.43) | MAPTNPC1RAB9APKMALDH1A1 | |
| SCHEMBL186752 | 0.85 | LMNA (0.51) | AKR1C3MAPTNPC1RAB9AMAPK1 | |
| SCHEMBL21890845 | 0.85 | RPS6KA3 (0.40) | MAPTTP53NPC1RAB9AMAPK1 | |
| SCHEMBL20694863 | 0.84 | GSK3B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590133-B2 | Dimer impurities of Apixaban and method to remove them | F.I.S.-FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2020-03-17 | — | — | US | disclosed |
| US-20170313695-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313695-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| US-9718779-B2 | Intermediate and polymorphs of 1-(4-methoxypheny1)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof | MSN LABORATORIES LIMITED (IN) | 2017-08-01 | — | — | US | disclosed |
| WO-2016035007-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | UNICHEM LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313695-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | VKORC1, VKORC1L1, CYP4X1 | AKR1C3 236/4885MAPT 4792/4885TP53 4851/4885 |
| US-10590133-B2 | Dimer impurities of Apixaban and method to remove them | F2, FGB, F8 | AKR1C3 2136/4885MAPT 4678/4885TP53 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.